Based on the key indicators related to NLS Pharmaceutics' liquidity, profitability, solvency, and operating efficiency, NLS Pharmaceutics AG may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, NLS Pharmaceutics' Total Current Assets are relatively stable compared to the past year. As of 11/26/2024, Common Stock is likely to grow to about 770.1 K, while Total Current Liabilities is likely to drop slightly above 4.5 M. Key indicators impacting NLS Pharmaceutics' financial strength include:
The essential information of the day-to-day investment outlook for NLS Pharmaceutics includes many different criteria found on its balance sheet. An individual investor should monitor NLS Pharmaceutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in NLS Pharmaceutics.
Net Income
(12.78 Million)
NLS
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Depreciation
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Long Term Debt
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Accumulated Other Comprehensive Income
Net Working Capital
Common Stock
Inventory
Short Long Term Debt
Capital Stock
Short Term Debt
Property Plant And Equipment Net
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Selling And Marketing Expenses
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past NLS Pharmaceutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of NLS Pharmaceutics' financial statements are interrelated, with each one affecting the others. For example, an increase in NLS Pharmaceutics' assets may result in an increase in income on the income statement.
NLS Pharmaceutics competes with Eliem Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company was incorporated in 2015 and is based in Zurich, Switzerland. Nls Pharmaceutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what NLS Pharmaceutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining NLS Pharmaceutics's current stock value. Our valuation model uses many indicators to compare NLS Pharmaceutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NLS Pharmaceutics competition to find correlations between indicators driving NLS Pharmaceutics's intrinsic value. More Info.
NLS Pharmaceutics AG is regarded fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, NLS Pharmaceutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NLS Pharmaceutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
NLS Pharmaceutics Systematic Risk
NLS Pharmaceutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. NLS Pharmaceutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on NLS Pharmaceutics correlated with the market. If Beta is less than 0 NLS Pharmaceutics generally moves in the opposite direction as compared to the market. If NLS Pharmaceutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one NLS Pharmaceutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of NLS Pharmaceutics is generally in the same direction as the market. If Beta > 1 NLS Pharmaceutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in NLS Pharmaceutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NLS Pharmaceutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of NLS Pharmaceutics growth as a starting point in their analysis.
NLS Pharmaceutics November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of NLS Pharmaceutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NLS Pharmaceutics AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of NLS Pharmaceutics AG based on widely used predictive technical indicators. In general, we focus on analyzing NLS Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NLS Pharmaceutics's daily price indicators and compare them against related drivers.
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.